Icariin as a Modulator of Cancer Cell Biology: Integrated Control of Proliferation, Cell Death Programs, Metastasis Signaling, and Delivery Challenges

Icariin, a prenylated flavonoid derived from plants of the Epimedium genus, has attracted increasing attention due to its broad spectrum of pharmacological activities, particularly its anticancer potential. Accumulating evidence indicates that icariin exerts strong inhibitory effects on tumor initiation, progression, and metastasis through modulation of multiple cellular and molecular pathways. Icariin regulates critical signaling cascades, including PI3K/AKT, MAPK, Wnt/β‐catenin, and NF‐κB, leading to the suppression of proliferation, induction of apoptosis, inhibition of angiogenesis, and reversal of multidrug resistance. Furthermore, icariin demonstrates the ability to modulate tumor immune responses and enhance the efficacy of conventional chemotherapeutic and radiotherapeutic regimens. Preclinical studies across diverse cancer models, such as breast, prostate, colorectal, and lung cancers, consistently highlight its therapeutic promise. Despite these encouraging results, limitations remain regarding its poor bioavailability and pharmacokinetic profile. Recent advances in nanotechnology‐based drug delivery systems have shown potential to overcome these challenges, improving stability, absorption, and targeted delivery. Collectively, current findings underscore icariin as a multifunctional natural compound with significant promise for cancer prevention and therapy. Future research should focus on well‐designed clinical studies and innovative delivery strategies to fully translate its anticancer potential into clinical applications.